Prévisions
L'objectif de cours moyen des analystes est de 100,77 € (+419,97 %). La médiane est de 132,02 € (+581,22 %).
| Acheter |
5 |
| Conserver |
0 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Bright Minds Biosciences raises $175 million through placement of common shares
Bright Minds Biosciences placed 1,945,000 common shares at $90.00 each, generating gross proceeds of $175.05 million. The syndicate banks were granted a 30-day overallotment option for up to 291,750 additional shares. The funds are intended to finance clinical trials (including the start of phase 1 for BMB-105), research and development of earlier programs, and general corporate purposes. » Plus sur de.investing.com
Bright Minds Biosciences sets price for share offering at $90
Bright Minds Biosciences has set the price for a public offering of 1,945,000 common shares at $90.00 per share and expects gross proceeds of about $175.05 million. The underwriters were granted a 30-day option to purchase up to 291,750 additional shares at the same price; closing is expected on January 9, 2026. The proceeds are intended to fund clinical trials for several drug candidates; the company has simultaneously ended its at-the-market program. Analysts mostly rate the stock as "Buy," and the share price and market capitalization have risen sharply after a strong rally. » Plus sur de.investing.com
Bright Minds Biosciences plans public offering of $100 million
Bright Minds Biosciences announced a public offering of common stock and pre-funded warrants totaling $100 million and granted the underwriters a 30-day option to purchase up to 15% of the offered common stock. Proceeds are intended to fund clinical trials for drugs targeting absence seizures, DEE and Prader‑Willi syndrome, as well as Phase 1 studies for BMB‑105, earlier-stage research and general corporate purposes. The offering is being made under an F-3 registration; Jefferies, TD Cowen, Piper Sandler and Cantor are serving as joint book-running managers. The company reports a strong balance sheet with more cash than debt and a current ratio of 36.1. » Plus sur de.investing.com
Bright Minds Biosciences stock rises after positive phase‑2 data on BMB‑101
The stock of Bright Minds Biosciences rose about 5% after positive topline results from the phase‑2 BREAKTHROUGH study of the selective 5‑HT2C agonist BMB‑101 in epilepsy‑associated disorders. In the 24‑patient study, median seizure frequency in absence epilepsy fell by 73.1% (p=0.012) and severe motor seizures in DEE patients by 63.3%. BMB‑101 also significantly improved REM sleep, was mostly well tolerated and showed no treatment‑related serious adverse events. Bright Minds is preparing global registration trials for DEE and absence epilepsy and plans a study in Prader‑Willi syndrome in Q1 2026. » Plus sur de.investing.com
Bright Minds launches Prader‑Willi program and nominates BMB-105 as clinical candidate
Bright Minds has launched a Prader‑Willi syndrome (PWS) program and nominated BMB-105 as a new clinical candidate. The company is starting the double‑blind, randomized phase‑2a NOVA study with BMB-101 to evaluate efficacy and safety in PWS patients and plans a parallel randomized, placebo‑controlled phase‑1 study of BMB-105 in healthy volunteers. BMB-101 has shown good tolerability so far in epilepsy studies, with top‑line data expected in January 2026; Bright Minds aims to accelerate time to market by roughly one year with BMB-105. » Plus sur de.investing.com
Données financières
Au dernier trimestre, BRIGHT MINDS BIOSCIENCES a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -1,52 M €
| (EUR) | juin 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | -12,32 k | - |
| Bénéfice net | -1,52 M | 53,56 % |
| EBITDA | -7,22 M | 121,62 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 189,68 M € |
Nombre d'actions | 9,86 M |
Plus haut/bas sur 52 semaines | 112,67 € - 15,84 € |
| Dividendes | Non |
Bêta | 0,09 |
Ratio P/E | -9,97 |
Ratio PEG | 0,13 |
Ratio P/B | 0,92 |
Ratio P/S | 0,00 |
Profil de l'entreprise
Bright Minds Biosciences Inc., une entreprise de biosciences en phase précoce (préclinique), développe des médicaments ciblant la sérotonine (5-HT) afin d'améliorer la vie des patients atteints de maladies graves et invalidantes. Son portefeuille d'agonistes sélectifs des récepteurs 5-HT comprend les agonistes 5-HT2C, 5-HT2A et 5-HT2C/A destinés au traitement de l'épilepsie, de la douleur et des troubles neuropsychiatriques. La société a noué des collaborations avec les National Institutes of Health pour le traitement de l'épilepsie, avec l'University of Texas Medical Branch pour traiter les troubles du contrôle des impulsions, tels que l'hyperphagie boulimique, ainsi qu'avec le Medical College of Wisconsin. La société a été constituée en 2019 et son siège social se trouve à Vancouver, au Canada.
| Nom | BRIGHT MINDS BIOSCIENCES |
| PDG | Ian McDonald |
| Siège social | New York,
ny Canada |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 22/03/2021 |
| Employés | 26 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | DRUG |